Recent

% | $
Quotes you view appear here for quick access.

Sangamo Biosciences Inc. Message Board

chi_town_oracle 68 posts  |  Last Activity: 11 hours ago Member since: Apr 2, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Tomorrow may be weird

    by kraftmacht Jun 23, 2016 9:32 PM
    chi_town_oracle chi_town_oracle 11 hours ago Flag

    I think the whole world is watching the UK. Especially Vlad Putin. He knows full well the outcomes of dis-unity. Russia today is a victim of dis-unity although one could easily say there was NO unity in the old Soviet. Even more destabilizing is Scotland's wish to remain IN the Union...

    The world is experiencing a gigantic leveling action as emerging-cheap labor countries exert pressure on some sectors of rich countries while providing profits to some sectors of very rich countries. The dividend class enjoys this action while the lower middle class is aghast as well as out of work.

    One might say: Trump will be the final destabilizer via actions against China. OR- China will change to avoid losing its biggest best labor customer.
    It can be a catastrophic game of chicken with the wrong moves turning the table upside down.

    I don't see much support from within the current GOP for Trump's China actions. I see support from certain DEMO constituencies for Trump's possible actions.

    But the world will NOT follow a flow of blather from Twitter by the leader of the free world whose heros seem to be repressive plutocrats ( "Putin didn't kill any journalists, did you see evidence that he killed one journalists because I didn't see any")
    How does the GOP close its ear to this kind of talk about Putin? I used to think we had a better chance of the North and South poles flipping their polarity in our lifetime than to hear a candidate for leader of the FREE world expressing admiration for a "dictator"...-chi

  • chi_town_oracle by chi_town_oracle Jun 23, 2016 12:53 PM Flag

    Short position up 500K at end of May...not typical short action heading into data release. Why?

    Possibly the shorts know they are being set up via the lower trending price, meaning they have NO PLAY at $2.30 range.

    I figure typical shorts will lose significantly on data release, then try to short it backwards to sort of average short down---THEN---the larger players will enter as they know the shorts will have less of play. If you follow the action of CPXX, the shorts tried to average downward on their initial losses by dumbly shorting more...pure desperation once the future was known.

    Same here...I figure they are about to contribute at least $2/share and possibly more. But my opinion is insignificant...the strategy of bigger players who see a need for CYTR to trade 20M shares a day to allow the shorts to escape.

    When positive data is released, watch for a fall back ( shorts acting) to buy more shares as the future is known and on the side of all LONGS--chi

  • Reply to

    Cowen Group Bought New Position Reported 3/31/2016

    by parisite76 Jun 22, 2016 11:05 AM
    chi_town_oracle chi_town_oracle Jun 22, 2016 8:30 PM Flag

    Same to you my friend!- chi

  • Reply to

    Cowen Group Bought New Position Reported 3/31/2016

    by parisite76 Jun 22, 2016 11:05 AM
    chi_town_oracle chi_town_oracle Jun 22, 2016 11:22 AM Flag

    PARI...I would put Cowen into the logical buyer group, much like many of us.
    That simple yet sound thesis: ALDOX beat DOX by unloading IN/ON the cancer while NOT harming the heart.

    I believe on this basis alone, in addition to other potential aspects, the FDA must approve ALDOX to REPLACE DOX--chi

  • Reply to

    Life-saving EpiPens see huge price spike

    by uptick77777 Jun 20, 2016 3:35 PM
    chi_town_oracle chi_town_oracle Jun 21, 2016 10:51 AM Flag

    Loko...my guess is TEVA is going to be very engaged with ATRS after the big acquisition closes. I cannot wait to dig thru the list of drugs TEVA will have to market- chi

  • Reply to

    Life-saving EpiPens see huge price spike

    by uptick77777 Jun 20, 2016 3:35 PM
    chi_town_oracle chi_town_oracle Jun 20, 2016 5:11 PM Flag

    matar= don't worry too long, the market has a way of seeing opportunities and rapidly addressing them. Expect a challenger to emerge sooner than usual- chi

    Kudos to Loko for his never ending, high quality DD on ATRS!!!!!

  • Reply to

    shorts are still messing around

    by amerelhaija Jun 20, 2016 3:33 PM
    chi_town_oracle chi_town_oracle Jun 20, 2016 4:03 PM Flag

    Amere- shorts will do that...while LONGS are exhausted...SHORTS always trying to snag a STOP which then triggers another STOP and down the line...UNTIL buyers step back in.

    The company's signals are SOP except for the data release delay...I would have expected their CRO to be able to accurately predict a window...but crunching Ph3STS data is pivotal and must be 100% accurate.

    My simple take, Dox vs. the comparator's outcomes on each type of STS will be beaten by ALDOX...by how much, I cannot say.

    But when gauging side effects of most active chemos, an oncologist must be careful with DOX and the heart...I believe this study will lift plenty of heart damage worry by the oncologist for applying ALDOX to the cancer in question. For this reason alone, ALDOX must be approved...but its effectiveness will also be greater than most of the other comparators.--chi

  • Reply to

    4 Key takeaways from today's PR:

    by chi_town_oracle Jun 6, 2016 1:10 PM
    chi_town_oracle chi_town_oracle Jun 6, 2016 3:35 PM Flag

    You speak with forked tongue. I surmise you about to lose a foot and a half of altitude,shortie-chi

  • Reply to

    4 Key takeaways from today's PR:

    by chi_town_oracle Jun 6, 2016 1:10 PM
    chi_town_oracle chi_town_oracle Jun 6, 2016 2:29 PM Flag

    Which study are you referring to that was PR'd today by the company?-chi

  • chi_town_oracle by chi_town_oracle Jun 6, 2016 1:10 PM Flag

    1. GBM study: The median overall survival was 8.6 months (95% CI: 7.8-10.1) with seven patients still on study and being followed.

    This study provides the first evidence that aldoxorubicin's albumin-binding mechanism allows it to cross the blood-brain barrier, unlike doxorubicin, and kill glioblastoma cells. Following the completion of this trial, CytRx will evaluate the clinical path forward for aldoxorubicin as a treatment for advanced GBM.

    Note to Adam: read up on this and then get your HS diploma!

    2. To date, in all studies involving some 550 patients receiving ALDOX, there have been NO heart damage reports or issues. Clearly this represents a significant differentiator vs. standard Dox.

    Note to Adam: once again science has made you look small and foolish...maybe even actionable?

    3. Treatment of HIV-associated Kaposi's sarcoma with aldoxorubicin (ongoing)
    To date, significant anti-tumor activity has been observed. At these low doses, 11 of 13 (85%) patients have achieved partial responses at cycle 4, and at the end of the study, 8 of 12 (67%) patients have demonstrated partial responses. Two patients continue to be treated.
    The high level of activity and important tolerability of low dose aldoxorubicin will allow long term usage in this very difficult to treat group of patients.

    Note to Adam: a hard to treat group of patients are being successfully treated w/ low doses of Aldox...maybe you might want to post up a review of this progress of Aldoxorubicin.

    4. Aldox is working on different types of cancers, some of which were of the soft tissue type similar to what is being analyzed right now in the STS Ph3. This is the deep positive of today's PR, IMO- chi

  • Reply to

    Question...

    by tamucs2003 Jun 1, 2016 1:54 PM
    chi_town_oracle chi_town_oracle Jun 1, 2016 7:08 PM Flag

    DID you digest my message? Adam made a case out of "the central labs readings" not matching OTHER DOX readings for effectiveness. He ignored CYTR's own investigator's reading. Why? he is a #$%$ bag. Now your DD is done. Good luck shilling for Adam and tell him, a pox be upon his house- chi

  • Reply to

    Question...

    by tamucs2003 Jun 1, 2016 1:54 PM
    chi_town_oracle chi_town_oracle Jun 1, 2016 2:40 PM Flag

    Correct, but dum-dums post on here based on their own motivations. Adam never mentions CYTR's investigator's number, he prefers the Central Labs #, so his beef is with them not with CYTR-- yet this dum dum appears to dredge up a mistake and post it like it was an honest concern, without doing scant diligence--pathetic!-chi

  • Reply to

    Question...

    by tamucs2003 Jun 1, 2016 1:54 PM
    chi_town_oracle chi_town_oracle Jun 1, 2016 2:08 PM Flag

    Re-read your question-- it makes no sense. And it was NOT what Adam posed. Further, his real "point" has been debunked from every angle possible...read the board.

    Does ALDOX work? go read the studies- the answer is HELL YES. Does ALDOX work better than DOX? Double Hell Yes. Adam should be sued. Did he reveal his "short source" of ZERO credibility? Go ask Adam-chi

  • chi_town_oracle by chi_town_oracle May 31, 2016 1:53 PM Flag

    Adam set the shorts up really bad on the CPXX bonfire. CYTR could be just as heady.

    Shorts were burned daily, even when they tamped CPXX back down, even on Friday when they shorted CPXX and now they are re-toast. HUGE LOSSES because they are fatally stupid to assume Adam knows what he is talking about. He plays the micro cap percentage and got caught with his foot in his mouth.

    There is absolutely NO WAY- NOT POSSIBLE-CAN'T HAPPEN TWICE- AGAINST ALL ADAM ODDS--MOONSHOT NEIN- NIX ZO GOOT--ISN'T OUR PIZZA MR. HAND! chi

  • as long as its real close--chi

  • chi_town_oracle chi_town_oracle May 31, 2016 12:21 PM Flag

    GOVX- 20-30 range-- a lot of future expectations will be set by Ms.Ware in that she is really controlling production to meet demand based on what her current projections are. IF she projects 300-400M in year one, post approval plus 3 months-- wow is the word. I think this is in the ballpark.

    What is exciting for patients as well as shareholders is a drug that extends life and lessens side effects. Since the company is likely to know everywhere DOX has a footprint, it can quickly swoop in and offer a better alternative very quickly. This is a huge benefit for accelerated revenue ramp, IMO-chi

  • chi_town_oracle chi_town_oracle May 31, 2016 12:11 PM Flag

    Data release is NOT likely. Dr. L will be on that one...but this could set the table for what is to follow AFTER the Ph3 data is released. Also, they could be speaking about NEW developments for a post-ALDO approved world! All positive--chi

  • chi_town_oracle chi_town_oracle May 28, 2016 10:01 PM Flag

    You spout #$%$ to manipulate the SP downward...for your own menial gain-YOU will NOT be forgotten--chi

  • Take dead fish. Put in oven set to 200 degrees. Stand around and whiff. THIS ADAM HIT PIECE STINKS WORSE THAN THAT!- chi

  • chi_town_oracle chi_town_oracle May 26, 2016 4:23 PM Flag

    Lower sidefx = higher Aldox dosing= greater cancer killing firepower...again, is this a STS higher likely FDA approval? I think so-chi

SGMO
5.51-0.41(-6.93%)Jun 24 4:00 PMEDT